Lantern Pharma (LTRN) analyst forecast and price target
Analyst forecast
Consensus of 3 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Lake Street | Initiated Coverage | Buy | $25.00 | Apr 2, 2025 |
| HC Wainwright & Co. | Maintained | Neutral | — | Apr 25, 2024 |
| EF Hutton | Maintained | Buy | $11.00 | Aug 10, 2023 |
| EF Hutton | Maintained | Buy | $11.00 | Jun 26, 2023 |
| EF Hutton | Maintained | Buy | $11.00 | Mar 21, 2023 |
| EF Hutton | Maintained | Buy | $11.00 | Feb 15, 2023 |
Frequently asked questions
Is LTRN a buy, sell, or hold?
Analysts covering Lantern Pharma currently average a Buy rating: 3 buy, 0 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on LTRN?
On Apr 2, 2025, Lake Street initiated coverage of Lantern Pharma at Buy with a price target of $25.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.